Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Novartis
Woman and Man Max 99 years
Novartis Vaccines and Diagnostics S.r.l
Update Il y a 4 ans
Trial conducted in more then one site to assess safety of the Novartis vaccine against meningititis B injected at 0 and after 2 months in adults at risk because managing meningoccocus type B or travelling in geographic area where Meningitis B is highly present Studio condotto in piu' centri per valutare la sicurezza del vaccino Novartis contro la meningite B quando somministrato a 0 e dopo due mesi in adulti a rischio poiche' sono a contatto con meningococco di tipo B o viaggiano in aree geografiche dove la meningite B e' altamente presente
To descriptively assess the safety of Novartis rMenB+OMV NZ in healthy at-risk adults when administered at a 0, 2- month schedule, throughout the clinical study. valutare la sicurezza del vacci...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis
Update Il y a 6 ans
Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis
The purpose of this study is to assess the safety, tolerability, and efficacy of AEB071 as a therapy for uveitis. Vision improvement and reduction in the swelling of retina will be measure...
Country
United States
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Novartis Pharma
Update Il y a 4 ans
Essai de phase 1b, visant à déterminer la dose de BKM120, un inhibiteur oral de la phosphatidyl-inositol 3-kinase, à administrer en association avec l’imatinib, chez des patients ayant une tumeur stromale gastro-intestinale, après échec d’un traitement par imatinib et sunitinib. [essai clos aux inclusions]
L’objectif de cette étude est d’évaluer la tolérance, la sécurité d’emploi et l’activité préliminaire d’un traitement associant de la clofarabine à l'idarubicine et à la cytarabine, chez des patients ...
Country
France
organs
Tumeurs stromales digestives (GIST)
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man
Between 18 years
and 99 years
Novartis Pharma
Update Il y a 4 ans
Étude CINC280X2108 : étude de phase 1b-2 randomisée comparant la tolérance et l’efficacité du spartalizumab associé à du capmatinib par rapport au spartalizumab seul, chez des patients ayant un cancer hépatocellulaire avancé. [Informations issues du site clinicaltrials.gov et traduites par l'INCa]
Le carcinome hépatocellulaire est un cancer primitif du foie qui se développe, dans la grande majorité des cas, à partir des cellules du foie déjà endommagées par une maladie chronique ou une cirrhose...
Country
France
organs
Primitif du foie
Specialty
Thérapies Ciblées
,
Imagerie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
Safety and efficacy of osilodrostat (LCI699) for the treatment of patients with Cushing's disease
To compare the complete response rate at the end of the 8-week period of randomized withdrawal (Week 34) between patients randomized to continued LCI699 therapy vs. placebo.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma S.A.S
Update Il y a 4 ans
Etude prospective, randomisée, en ouvert évaluant le bénéfice clinique sur les hypoglycémies après 6 mois de l’addition de la vildagliptine versus celle d’un autre antidiabétique oral, chez des patients âgés diabétiques de type 2, insuffisamment contrôlés par la metformine en monothérapie
L’objectif principal est de comparer dans les deux groupes de traitement, le pourcentage de patients n’ayant présenté aucune hypoglycémie (épisodes confirmés par automesure de la glycémie capillaire o...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Service AG
Update Il y a 4 ans
A phase IIIb, open-label, multi-center 12 month study to evaluate the safety, tolerability and efficacy of ranibizumab (0.3 and/or 0.5 mg) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration
The primary objective of this study is to estimate the incidence of ocular adverse events (AEs) in patients with CNV secondary to AMD who are treated with 0.3 and/or 0.5 mg intravitreal ranibizumab.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
Study of safety and efficacy of EGF816 in combination with INC280 in non-small cell lung cancer patients with EGFR mutation
Phase Ib part: To estimate the MTD or RP2D of EGF816 in combination with INC280 Phase II part: To estimate the preliminary anti-tumor activity of EGF816 in combination with INC280
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Farmacéutica, S. A
Update Il y a 4 ans
Estudio abierto de re-tratamiento con Aclasta® en pacientes que han presentado recaída de la Enfermedad ósea de Paget y que participaron en los estudios de registro CZOL446K2304 y CZOL446K2305
El objetivo de eficacia principal es demostrar que a los pacientes con Enfermedad ósea de Paget que habían respondido al ZOL y que posteriormente presentaron una recaída se les puede normalizar de mod...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
Study to compare a tacrolimus Hexal® based regimen versus a Prograf® based regimen in renal transplantation
PHASE I: To demonstrate that the pharmacokinetics of Tacrolimus Hexal® assessed by the ratio of the AUC0-12h over a one month period post-transplantation is comparable to Prograf® in renal transplant...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
8
9
10
11
12
13
14
15
16
17
Next